Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Investment analysts at Cantor Fitzgerald issued their FY2018 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued on Monday. Cantor Fitzgerald analyst E. Piros forecasts that the biotechnology company will earn ($0.66) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $5.00 target price on the stock.
A number of other equities analysts have also recently commented on ARWR. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a report on Monday, November 27th. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. B. Riley began coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective on the stock. Finally, Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $4.13.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. The business had revenue of $8.71 million for the quarter, compared to analyst estimates of $7.32 million.
In related news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares in the company, valued at approximately $3,499,433.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of ARWR. OppenheimerFunds Inc. grew its position in Arrowhead Pharmaceuticals by 110.0% during the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after acquiring an additional 3,300,000 shares during the last quarter. First Manhattan Co. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $11,707,000. ING Groep NV bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth $3,500,000. Allianz Asset Management GmbH bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $1,958,000. Finally, Alps Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $305,000. Institutional investors and hedge funds own 20.48% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.